| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 808301 | 25 ug | $245 | ||
| 808302 | 100 ug | $595 |
| Application | FC |
|---|---|
| Format | Liquid, PE |
| Expression Host | CHO |
| Target Name | CTLA4, CD152 |
| Species | Human |
| Sources | Recombinant Human CTLA4 Protein (Ala37-Phe162) with C-terminus Fc-tag is expressed in CHO cell and conjugated to PE. |
| Accession Number | P16410 |
| Molecular Weight | The protein has a predicted molecular weight of 39.7 kDa. Under DTT-reducing conditions, it migrates at approximately 50 kDa on SDS-PAGE prior to conjugation. |
| Affinity Tag | C-Fc |
| Regulatory Status | RUO |
| Formulation | 1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein |
| Endotoxin level | Not tested |
| Protein Concentration | 25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration. |
| Storage and Handling | Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2–8°C for up to six months. |
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152, is an immune checkpoint receptor found on T cells. It shares 30% homology with CD28 and binds to the same ligands, B7.1/CD80 and B7.2/CD86, but with higher affinity. After T-cell activation, increased CTLA-4 expression leads to immune suppression by binding to CD80/CD86, inhibiting further T-cell activation through a process called trans-endocytosis.CTLA-4 is crucial for immune regulation and tolerance, especially on regulatory T cells (Tregs). Soluble CTLA-4 (sCTLA-4) further enhances Treg function and is linked to autoimmune diseases like type 1 diabetes. Additionally, CTLA-4 plays a role in chronic lymphocytic leukemia (CLL) progression.Due to its immune-modulatory role, CTLA-4 is targeted in cancer therapy. Ipilimumab, a monoclonal antibody that blocks CTLA-4, is approved for melanoma and is being explored for other cancers.
PE Conjugated Human CTLA4 Protein (C-Fc) TDS
Have a product or application question? Consult our FAQs or contact us.
